ATE282634T1 - Chaperonin 10 - Google Patents

Chaperonin 10

Info

Publication number
ATE282634T1
ATE282634T1 AT95902003T AT95902003T ATE282634T1 AT E282634 T1 ATE282634 T1 AT E282634T1 AT 95902003 T AT95902003 T AT 95902003T AT 95902003 T AT95902003 T AT 95902003T AT E282634 T1 ATE282634 T1 AT E282634T1
Authority
AT
Austria
Prior art keywords
seq
antibodies
cpn
cpn10
raised against
Prior art date
Application number
AT95902003T
Other languages
German (de)
English (en)
Inventor
Halle Morton
Alice Christina Cavanagh
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE282634T1 publication Critical patent/ATE282634T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
AT95902003T 1993-11-30 1994-11-30 Chaperonin 10 ATE282634T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
PCT/AU1994/000740 WO1995015338A1 (en) 1993-11-30 1994-11-30 Chaperonin 10

Publications (1)

Publication Number Publication Date
ATE282634T1 true ATE282634T1 (de) 2004-12-15

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902003T ATE282634T1 (de) 1993-11-30 1994-11-30 Chaperonin 10

Country Status (11)

Country Link
US (3) US6113899A (enExample)
EP (2) EP0731811B1 (enExample)
JP (3) JP3987104B2 (enExample)
AT (1) ATE282634T1 (enExample)
AU (2) AU684578B2 (enExample)
CA (1) CA2177179C (enExample)
DE (1) DE69434137T2 (enExample)
ES (1) ES2233938T3 (enExample)
NZ (2) NZ276670A (enExample)
PT (1) PT731811E (enExample)
WO (2) WO1995015338A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
WO1999002989A1 (en) * 1997-07-10 1999-01-21 Medical Research Council Chaperone fragments
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
DK1399744T3 (da) * 2001-06-27 2008-09-22 Janssen Pharmaceutica Nv EPF-receptorassays, forbindelser og terapeutiske præparater
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
KR20080098579A (ko) * 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
KR20080075505A (ko) * 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
BRPI0911676A2 (pt) 2008-04-11 2016-11-29 Cbio Ltd polipeptídeo cpn10 isolado, ácido nucléico isolado, construção de expressão, célula hospedeira, anticorpo, composição farmacêutica, método para tratar ou prevenir uma doença, método para modular a sinalização do prr, método para modular a produção e/ou a secreção de um ou mais imunomoduladores, método para inibir a produção e/ou a secreção de um ou mais imunomoduladores, método de identificação de um composto que se liga a um polipeptídeo, método para rastrear um coposto e um ligante de prr e variante funcional, derivado, homólogo, análogo ou fragmento do polipeptídeo
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005498A1 (en) * 1985-03-12 1986-09-25 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
WO1988004779A1 (en) * 1986-12-22 1988-06-30 University Of Queensland Method of treatment of mammals using antibodies to early pregnancy factor (epf)
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.

Also Published As

Publication number Publication date
EP0731811A1 (en) 1996-09-18
AU684578B2 (en) 1997-12-18
US6113899A (en) 2000-09-05
WO1995015338A1 (en) 1995-06-08
NZ276670A (en) 1998-01-26
EP0731811A4 (en) 2003-05-28
EP0731811B1 (en) 2004-11-17
CA2177179C (en) 2006-10-17
EP0733071A4 (en) 1997-02-26
ES2233938T3 (es) 2005-06-16
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
NZ276672A (en) 1998-01-26
AU1103695A (en) 1995-06-19
US6417334B1 (en) 2002-07-09
AU684577B2 (en) 1997-12-18
AU1103495A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
JP3545408B2 (ja) 2004-07-21
WO1995015339A1 (en) 1995-06-08
JP2004067698A (ja) 2004-03-04
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
US7358329B2 (en) 2008-04-15
PT731811E (pt) 2005-04-29
JP3986481B2 (ja) 2007-10-03
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
CA2177179A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
EP0731811A4 (en) CHAPERONINE 10
ATE368053T1 (de) Antimikrobielle peptide
NZ333999A (en) GnRH-leukotoxin chimeric proteins for use in vaccines
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
ATE355074T1 (de) Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
GB9108652D0 (en) Immunoreactive compounds
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP1619202A3 (en) immunotherapeutic methods using epitopes of wt-1 and gata-1
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ZA913389B (en) Variant cd44 surface proteins,coding therefor,antibodies thereagainst and uses thereof
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
WO1993019178A3 (en) Peptides useful for inducing tolerance
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
ATE395361T1 (de) Das h-y antigen
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
GR3020185T3 (en) Antibody inductor peptides inhibiting retroviruses of the hiv type and antibodies specific for said peptides
ATE315646T1 (de) Leukocyten-aktivierender faktor
NZ606260A (en) Novel polypeptides involved in immune response
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
WO2001070774B1 (en) Human t cell response to mhc-binding motif clusters
SE0002738D0 (sv) Electric actuator
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call
WO2000026240A3 (en) Streptococcal alpha2m-binding protein
SE0002728D0 (sv) New compound

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties